169 related articles for article (PubMed ID: 38552356)
1. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
2. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
3. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
5. Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation.
Cui S; Shin YJ; Ko EJ; Lim SW; Ju JH; Lee KI; Lee JY; Yang CW; Chung BH
Stem Cell Res; 2021 Mar; 51():102214. PubMed ID: 33545641
[TBL] [Abstract][Full Text] [Related]
6. Generation of the induced pluripotent stem cell line UKWNLi005-A derived from a patient with the GLA mutation c.376A > G of unknown pathogenicity in Fabry disease.
Breyer M; Klein T; Klug K; Klopocki E; Üçeyler N
Stem Cell Res; 2022 May; 61():102747. PubMed ID: 35325818
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease.
Miyajima T; Saito R; Yanagisawa H; Igarashi M; Wu C; Iwamoto T; Eto Y
J Inherit Metab Dis; 2023 Jan; 46(1):143-152. PubMed ID: 36220782
[TBL] [Abstract][Full Text] [Related]
8. Generation of the human induced pluripotent stem cell line (UKWNLi001-A) from skin fibroblasts of a woman with Fabry disease carrying the X-chromosomal heterozygous c.708 G > C (W236C) missense mutation in exon 5 of the alpha-galactosidase-A gene.
Klein T; Günther K; Kwok CK; Edenhofer F; Üçeyler N
Stem Cell Res; 2018 Aug; 31():222-226. PubMed ID: 30130681
[TBL] [Abstract][Full Text] [Related]
9. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
10. Functional evaluation of a novel GLA causative mutation in Fabry disease.
Li P; Zhang L; Xiong Q; Wang Z; Cui X; Zhou YA; Wang Y; Xiao H; Wu C
Mol Genet Genomic Med; 2019 Sep; 7(9):e864. PubMed ID: 31321922
[TBL] [Abstract][Full Text] [Related]
11. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
12. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.
Varela P; Carvalho G; Martin RP; Pesquero JB
Metab Brain Dis; 2021 Feb; 36(2):265-272. PubMed ID: 33156427
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the GLA gene in Mexican families with Fabry disease.
Gutiérrez-Amavizca BE; Gal A; Ortíz-Orozco R; Orth U; Prado Montes De Oca E; Gutiérrez-Amavizca JP; Figuera LE
J Genet; 2017 Mar; 96(1):161-164. PubMed ID: 28360401
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease due to D313Y and novel GLA mutations.
Koulousios K; Stylianou K; Pateinakis P; Zamanakou M; Loules G; Manou E; Kyriklidou P; Katsinas C; Ouzouni A; Kyriazis J; Speletas M; Germenis AE
BMJ Open; 2017 Oct; 7(10):e017098. PubMed ID: 28988177
[TBL] [Abstract][Full Text] [Related]
17. Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system.
Cui S; Fang X; Lee H; Shin YJ; Koh ES; Chung S; Park HS; Lim SW; Lee KI; Lee JY; Yang CW; Chung BH
J Transl Med; 2023 Feb; 21(1):138. PubMed ID: 36814269
[TBL] [Abstract][Full Text] [Related]
18. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
[TBL] [Abstract][Full Text] [Related]
20. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
